# A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

> **NCT02666352** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Uprifosbuvir
- **DRUG:** Ruzasvir

## Key facts

- **NCT ID:** NCT02666352
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-22
- **Primary completion:** 2017-01-16
- **Final completion:** 2017-01-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02666352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02666352, "A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02666352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*